“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."
As ASE marks its 50th anniversary in Nashville, the meeting will showcase the latest echocardiography research, updated guidelines, the Kalmanson Lecture, and discussions on workforce challenges.